Merck's earnings call for Q2 2012 showed a continued momentum in their top and bottom-line growth despite global economic pressures and the imminent loss of exclusivity for SINGULAIR, a major revenue contributor. Their strong operational performance, solid pipeline progress, and successful expansion into high-growth markets like Japan and the emerging markets reflect positively. However, challenges such as foreign exchange impacts, European austerity measures, and anticipated rapid sales decline of SINGULAIR post-patent expiration could temper the stock's short-term performance. The company's strategic focus on innovation and diversified growth mitigates some risks, suggesting resilience but with near-term pressures.

[0]